Home
IFRX
IFRX News

Latest InflaRx N.V. (IFRX) News on May 20, 2025

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)

Simply Wall St.

9 days ago

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

13 days ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

InflaRx to Report First Quarter 2025 Results on May 7, 2025

GlobeNewswire

20 days ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

MT Newswires

21 days ago

Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

Insider Monkey

2 months ago

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

2 months ago

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

GlobeNewswire

2 months ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

GlobeNewswire

2 months ago

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

GlobeNewswire

3 months ago

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

GlobeNewswire

3 months ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire

3 months ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

MT Newswires

3 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

MT Newswires

3 months ago

InflaRx Slumps Premarket After Pricing $30 Million Offering of Ordinary Shares, Pre-Funded Warrants

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire

3 months ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire

3 months ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch

Simply Wall St.

4 months ago

Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

GlobeNewswire

4 months ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS

Pharmaceutical Technology

4 months ago

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

Zacks

4 months ago

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

MT Newswires

4 months ago

InflaRx Gets Marketing Approval for COVID-19 Therapy in Europe

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

GlobeNewswire

4 months ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

InflaRx Announces Participation in January Events in San Francisco

GlobeNewswire

4 months ago

InflaRx Announces Participation in January Events in San Francisco

US Penny Stocks To Watch In December 2024

Simply Wall St.

5 months ago

US Penny Stocks To Watch In December 2024

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

GlobeNewswire

5 months ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?

Insider Monkey

6 months ago

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?

MT Newswires

6 months ago

InflaRx Says Severe Covid Drug Gets EU Panel's Positive Opinion; Shares Rise Pre-Bell

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

GlobeNewswire

6 months ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Prenetics Global And 2 Other US Penny Stocks To Watch

Simply Wall St.

6 months ago

Prenetics Global And 2 Other US Penny Stocks To Watch

InflaRx Reports Q3 2024 Financial Results and Progress

TipRanks

6 months ago

InflaRx Reports Q3 2024 Financial Results and Progress

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Simply Wall St.

6 months ago

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx expects cash to fund operations into 2026

TipRanks

6 months ago

InflaRx expects cash to fund operations into 2026

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates

Zacks

6 months ago

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

GlobeNewswire

7 months ago

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

GlobeNewswire

8 months ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

GlobeNewswire

9 months ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

InflaRx Announces Participation in September Investor Events

GlobeNewswire

9 months ago

InflaRx Announces Participation in September Investor Events

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

Zacks

9 months ago

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

GlobeNewswire

10 months ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

GlobeNewswire

10 months ago

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance Monday Afternoon

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

GlobeNewswire

a year ago

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

InflaRx Hosts R&D Event Highlighting the Promise of INF904

GlobeNewswire

a year ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

GlobeNewswire

a year ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

GlobeNewswire

a year ago

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

GlobeNewswire

a year ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

Zacks

a year ago

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

GlobeNewswire

a year ago

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

GlobeNewswire

a year ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a year ago

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

InflaRx Appoints Jan Medina as Head of Investor Relations

GlobeNewswire

a year ago

InflaRx Appoints Jan Medina as Head of Investor Relations

Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher

Zacks

a year ago

Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher

Kopin Receives $1.4 Million Production Order For Specialized Weapon Sight Module

Business Wire

a year ago

Kopin Receives $1.4 Million Production Order For Specialized Weapon Sight Module

Planet Image International Limited Announces Closing of $5 Million Initial Public Offering

PR Newswire

a year ago

Planet Image International Limited Announces Closing of $5 Million Initial Public Offering

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

GlobeNewswire

a year ago

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions

Simply Wall St.

a year ago

InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions

Bowman Awarded $1.9 Million in New Arizona Mining Contracts

Business Wire

a year ago

Bowman Awarded $1.9 Million in New Arizona Mining Contracts

D-Wave Announces 1,200+ Qubit Advantage2™ Prototype in New, Lower-Noise Fabrication Stack, Demonstrating 20x Faster Time-to-Solution on Important Class of Hard Optimization Problems

Business Wire

a year ago

D-Wave Announces 1,200+ Qubit Advantage2™ Prototype in New, Lower-Noise Fabrication Stack, Demonstrating 20x Faster Time-to-Solution on Important Class of Hard Optimization Problems

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Business Wire

a year ago

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Business Wire

a year ago

Tillys Announces Leadership Transition

Freshpet, Tilly’s, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

Freshpet, Tilly’s, and More Stocks See Action From Activist Investors

Mega Matrix Corp. Appoints Xiangchen (Steven) Gao as Chief Operating Officer

GlobeNewswire

a year ago

Mega Matrix Corp. Appoints Xiangchen (Steven) Gao as Chief Operating Officer

American Public Education (APEI) Is Attractively Priced Despite Fast-paced Momentum

Zacks

a year ago

American Public Education (APEI) Is Attractively Priced Despite Fast-paced Momentum

Is American Public Education (APEI) Stock Undervalued Right Now?

Zacks

a year ago

Is American Public Education (APEI) Stock Undervalued Right Now?

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now

Simply Wall St.

a year ago

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now

Bassett Announces Regular Quarterly Dividend

GlobeNewswire

a year ago

Bassett Announces Regular Quarterly Dividend

Chatham Lodging Trust Announces Sale of Hotel

Business Wire

a year ago

Chatham Lodging Trust Announces Sale of Hotel

PetMeds® Announces new Chairman of the Board

PR Newswire

a year ago

PetMeds® Announces new Chairman of the Board

Ellington Residential Declares Monthly Common Dividend

Business Wire

a year ago

Ellington Residential Declares Monthly Common Dividend

Sangoma Named In The 2023 Gartner® Magic Quadrant™ For Unified Communications As A Service Report For Ninth Year

Business Wire

a year ago

Sangoma Named In The 2023 Gartner® Magic Quadrant™ For Unified Communications As A Service Report For Ninth Year

Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue

GlobeNewswire

a year ago

Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue

ACCESSWIRE

a year ago

iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024

Bit Digital, Inc. Announces Monthly Production Update for December 2023

PR Newswire

a year ago

Bit Digital, Inc. Announces Monthly Production Update for December 2023

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

GlobeNewswire

a year ago

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Canaan Secures Follow-On Purchase Orders from Cipher and Stronghold

PR Newswire

a year ago

Canaan Secures Follow-On Purchase Orders from Cipher and Stronghold

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES QUARTERLY CASH DIVIDEND.

PR Newswire

a year ago

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES QUARTERLY CASH DIVIDEND.

Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2023

PR Newswire

a year ago

Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2023

A Look At The Intrinsic Value Of AMREP Corporation (NYSE:AXR)

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of AMREP Corporation (NYSE:AXR)

Hemlo Explorers Announces Sale of Hawkins Gold Royalty

GlobeNewswire

a year ago

Hemlo Explorers Announces Sale of Hawkins Gold Royalty

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

Zacks

a year ago

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

7 Micro-Cap Stocks for Risk-Tolerant Investors to Buy in 2024

InvestorPlace

a year ago

7 Micro-Cap Stocks for Risk-Tolerant Investors to Buy in 2024

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

Zacks

a year ago

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone

Simply Wall St.

a year ago

Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone

The RMR Group Completes Acquisition of CARROLL Multifamily Platform

Business Wire

a year ago

The RMR Group Completes Acquisition of CARROLL Multifamily Platform

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

PR Newswire

a year ago

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Benign Growth For BGSF, Inc. (NYSE:BGSF) Underpins Its Share Price

Simply Wall St.

a year ago

Benign Growth For BGSF, Inc. (NYSE:BGSF) Underpins Its Share Price

Climb Global Solutions, Inc. (NASDAQ:CLMB) is a favorite amongst institutional investors who own 52%

Simply Wall St.

a year ago

Climb Global Solutions, Inc. (NASDAQ:CLMB) is a favorite amongst institutional investors who own 52%

Director Ali Mazanderani's Strategic Investment in Lesaka Technologies Inc

GuruFocus.com

a year ago

Director Ali Mazanderani's Strategic Investment in Lesaka Technologies Inc

First Community Announces Leadership Moves

PR Newswire

a year ago

First Community Announces Leadership Moves

Mama’s Creations Reports Third Quarter Fiscal 2024 Financial Results

GlobeNewswire

a year ago

Mama’s Creations Reports Third Quarter Fiscal 2024 Financial Results

GlobeNewswire

a year ago

AMREP Reports Second Quarter Fiscal 2024 Results

CMTL or MSI: Which Is the Better Value Stock Right Now?

Zacks

a year ago

CMTL or MSI: Which Is the Better Value Stock Right Now?

Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently

Simply Wall St.

a year ago

Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently

11 Best Water Stocks To Buy

Insider Monkey

a year ago

11 Best Water Stocks To Buy

AMREP Corporation's (NYSE:AXR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Simply Wall St.

a year ago

AMREP Corporation's (NYSE:AXR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Share on Social Networks: